VEA
DFTX

Virtus ETF Advisers’s Definium Therapeutics DFTX Stock Holding History

Virtus ETF Advisers’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,127
Closed -$70.5K – 644
2024
Q4 		$70.5K Buy
+10,127
New +$69.7K 0.03% 375

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtus ETF Advisers's DFTX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Definium Therapeutics (DFTX) in Q1 2025, closing a stake of 10,127 shares — an estimated $70.5K sold.

Virtus ETF Advisers first reported a position in DFTX in Q4 2024 and held it in 1 quarter. The position peaked at $70.5K in Q4 2024. 190 funds tracked by Wall St. Rank hold DFTX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Definium Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 10,127 Definium Therapeutics shares in Q1 2025, an estimated $70.5K.
  • Virtus ETF Advisers first reported a position in Definium Therapeutics in Q4 2024 and held it in 1 quarter.
  • Virtus ETF Advisers's Definium Therapeutics position peaked at $70.5K in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.